Opening of intermediate-conductance calcium-activated potassium channels (K Ca 3.1) produces membrane hyperpolarization in the vascular endothelium. Here, we studied the ability of two new K Ca 3.1-selective positive-gating modulators, SKA-111 and SKA-121, to (1) evoke porcine endothelial cell K Ca 3.1 membrane hyperpolarization, (2) induce endothelium-dependent and, particularly, endothelium-derived hyperpolarization (EDH)-type relaxation in porcine coronary arteries (PCA) and (3) influence coronary artery tone in isolated rat hearts. In whole-cell patchclamp experiments on endothelial cells of PCA (PCAEC), K Ca currents evoked by bradykinin (BK) were potentiated ≈7-fold by either SKA-111 or SKA-121 (both at 1 μM) and were blocked by a K Ca 3.1 blocker, TRAM-34. In membrane potential measurements, SKA-111 and SKA-121 augmented bradykinin-induced hyperpolarization. Isometric tension measurements in large-and small-calibre PCA showed that SKA-111 and SKA-121 potentiated endothelium-dependent relaxation with intact NO synthesis and EDH-type relaxation to BK by ≈2-fold. Potentiation of the BK response was prevented by K Ca 3.1 inhibition. In Langendorff-perfused rat hearts, SKA-111 potentiated coronary vasodilation elicited by BK. In conclusion, our data show that positive-gating modulation of K Ca 3.1 channels improves BK-induced membrane hyperpolarization and endothelium-dependent relaxation in small and large PCA as well as in the coronary circulation of rats. Positive-gating modulators of K Ca 3.1 could be therapeutically useful to improve coronary blood flow and counteract impaired coronary endothelial dysfunction in cardiovascular disease.
Altered function of the intermediate-conductance calcium-activated potassium channels (K Ca 3.1) [1, 2] has been suggested to accompany endothelial dysfunction observed in many cardiovascular disease states including diabetes [3] (for extensive review, see [4, 5] ). However, preserved K Ca 3.1 functions and ensuing EDH-mediated relaxations have also been reported [6] [7] [8] . So, regardless of whether the EDH system is impaired or preserved, pharmacological activation of K Ca 3.1 might constitute a therapeutic strategy to improve endothelial function in diseased coronary arteries and other vascular beds and may provide cardiovascular protection [4, 5, [9] [10] [11] [12] . This strategy may be advantageous over strategies targeting other vascular and smooth muscle potassium channels such as K ATP channels [13, 14] , K 2P channels [15, 16] and large-conductance K Ca 1.1 channels [17, 18] because K Ca 3.1 activation particularly favours endothelium-dependent relaxation [5] .
The current most selective and potent activator of K Ca 3.1, the benzothiazole SKA-31 [19] (for recent review, see [5] ), which has 10 times higher potency on K Ca 3.1 channels than on K Ca 2 channels, has been shown to produce vasodilation in coronary and skeletal muscle vascular beds [20, 21] , to lower blood pressure in normotensive and angiotensin-II-infused hypertensive mice [19] and to produce a short-lived depressor response in conscious dogs and pigs [22, 23] . However, at least in rodents, blood pressure-lowering doses of SKA-31 also produce severe bradycardia [21] and sedation [24] . This may be attributed to the activation of cardiac and neuronal K Ca 2 channels and therefore limits the use of SKA-31 for cardiovascular conditions.
In the present study, we tested the hypothesis that selective pharmacological activation of K Ca 3.1 is capable of potentiating endothelial hyperpolarization and endothelium-dependent relaxation to bradykinin (BK). For this purpose, we investigated the effect of the benzothiazole SKA-111 and the benzoxazole SKA-121, two new positive-gating modulators, in porcine large and small coronary arteries (PCA). SKA-111 and SKA-121 have, respectively, 120 times and 40 times higher selectivity for K Ca 3.1 channels over K Ca 2 channels [25] . We show that selective positive-gating modulation of K Ca 3.1 by SKA-111 and SKA-121 elicited K Ca 3.1 currents and hyperpolarization in porcine coronary artery endothelial cells (PCAEC) and selectively potentiated BK-induced endothelium-dependent and, particularly, EDH-type relaxation of PCA. In Langendorff-perfused rat hearts, SKA-111 potentiated bradykinin-induced reduction in coronary perfusion pressure (CPP).
Materials and Methods
Porcine coronary artery endothelial cells PCAEC were isolated from hearts kindly provided by the local slaughterhouse (Matadero Mercazaragoza, Zaragoza) as described previously [26] . In brief, PCAs, with an inner diameter of about 1-2 mm and an outer diameter of 2-3 mm, were carefully dissected and cleaned of surrounding tissue and fat, were cut open longitudinally and incubated in trypsin/ EDTA (0.25%/0.02%) in PBS without Ca 2+ /Mg 2+ (Biochrom KG, Berlin, Germany) for 30 min. Subsequently, PCAEC were scraped and aspirated from the luminal side using a pipette tip and seeded on cover slips. Cells were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% foetal calf serum (FCS) and 1% penicillin/streptomycin (Biochrom KG, Berlin, Germany). Before performing patch-clamp experiments, cover slips were transferred into the NaCl bath solution and the cells were used for electrophysiological measurements within ≈36 hr.
Patch-clamp electrophysiology
Whole-cell currents were measured using an EPC10-USB patch-clamp amplifier (HEKA Electronics, Germany) and Patchmaster ™ software as described in detail previously [26] . Currents were recorded using voltage ramps (U-ramps, −100 to 100 mV, 1 sec.) and a holding potential of 0 mV. Leak subtraction was omitted during data acquisition, although 'ohmic' leak of up to 0.3 nS was subtracted during analysis, if appropriate. Amplitudes of K + -outward currents were measured at 0 mV and normalized to cell capacitance. The standard pipette solution contained calcium to activate K Ca channels and was composed of (in mM): 140 KCl, 1 MgCl 2 , 2 EGTA, 1.71 CaCl 2 (1 μM [Ca 2+ ] free ) and 5 HEPES (adjusted to pH 7.2 with KOH). In another series of whole-cell experiments, we used a lower calcium concentration in the pipette solution of 0.7 mM ([Ca 2+ ] free 0.1 μM) to demonstrate that K Ca activation occurs only at a calcium concentration, which is above the threshold for K Ca 2.3/ K Ca 3.1 activation. In other experiments, we patch-clamped endothelial cell clusters using the pipette solution with low calcium to monitor current activation during BK and/or 5-HT stimulation in electrically coupled cells. In current-clamp experiments, we measured variations in membrane potential. Here, the calcium concentration in the pipette solution was 0.7 mM ([Ca 2+ ] free 0.1 μM). In all experiments, the NaCl bath solution was composed of (mM): 140 NaCl, 5 KCl, 1 MgSO 4 , 1 CaCl 2 , 10 glucose and 10 HEPES (adjusted to pH 7.4 with NaOH). Regarding cell capacitance, single cells had a mean capacitance of 9.4 ± 0.7 pF (n = 29 experiments). Cells in clusters were electrically coupled and exhibited higher capacitance values of 101 ± 13 pF (n = 30 experiments).
Gene expression studies
RNA isolation and reverse transcription: Total RNA from primary freshly isolated pig aortic endothelial cells was isolated with TriReagent (Sigma, St. Louis, USA) following the manufacturer's protocol and further purified using RNAeasy MinElute Cleanup kit (Qiagen, Hilden, Germany). Quantity and purity of extracted RNA samples were analysed by spectrophotometry (NanoDrop 1000; ThermoFisher, Waltham, MA, USA) before using them to reverse transcription or storing them at −80°C for a later use. Isolated RNA samples were also analysed for integrity and genomic DNA contamination by gel electrophoresis prior to their use in reverse transcription.
RT-PCR was performed by using the SuperScript II reverse transcriptase (Invitrogen, Carlsbad, USA) following the manufacturer's protocol. Random hexamers were used to synthesize cDNA. In order to detect mRNA expression of the channel genes (K Ca 2.1, K Ca 2.2, K Ca 2.3, K Ca 3.1) and endothelial nitric oxide synthase (eNOS, gene name NOS3), we used a standard PCR protocol with an initial denaturation step at 94°C for 2 min., 40 cycles (94°C denaturation for 15 sec., 53°C annealing for 30 sec. and 72°C extension for 30 sec.), followed by a final extension step at 72°C for 5 min., using a MyCycler thermal cycler (BioRad, Hercules, USA) and Taq polymerase (Stratec, Birkenfeld, Germany).
Myography on porcine coronary arteries
Isometric myography on large PCA rings was performed as described previously [27, 28] . In brief, rings were mounted onto an isometric force transducer (Pioden UF1, Graham Bell House, Canterbury, UK). The bath solution was a Krebs buffer (37°C; equilibrated with 95% O 2 /5% CO 2 ) and consisted of (mM): 120 NaCl, 24.5 NaHCO 3 , 2.4 CaCl 2 , 4.7 KCl, 1.2 MgSO 4 , 1 KH 2 PO 4 and 5.6 glucose, pH 7.4. Rings were pre-stretched to an initial tension of 1 g (10 mN). Changes in force were recorded using a Mac Lab System/8e program (AD Instruments Inc, Milford, MA, USA) at a sample rate of 0.5 sec. Small coronary arteries (internal lumen diameters of 250-400 μm) isolated from the left ventricle of hearts obtained at Danish Crown (Horsens, Denmark) were mounted in microvascular myographs and stretched as previously described for lamb coronary arteries [29] . To measure EDH-type relaxation in large PCA, the buffer contained the NO-synthase blocker, N-ω-nitro-L-arginine (L-NNA, 300 μM), and the cyclooxygenase blocker, indomethacin (INDO) (10 μM). In experiments on small PCA, we used 100 μM NG-nitro-L-arginine methyl ester (L-NAME) instead of L-NNA. After an equilibration period of 40 min., compounds, alone or in combination, or vehicle (DMSO), were tested as follows: 1) pre-incubation of rings with one or two compounds for 5 min.; 2) pre-contraction with 5-HT (1 μM, 10 min.); 3) cumulative relaxation with increasing doses of BK (10 nM, 100 nM and 1 μM, over 10 min.); 4) washout over 10 min. Finally, rings were contracted with KCl (60 mM) buffer for 10 min., and relaxation was induced by adding sodium nitroprusside (10 μM). In other experimental series, we conducted the experiments in the absence of L-NNA (or L-NAME) and INDO. Under these conditions, 5-HT caused smaller contractions above the low spontaneous tone in the large PCA (data not shown).
Data analysis
We evaluated absolute increases in force to 5-HT or to 60 mM KCl. EDH-type relaxations were determined as % change of pre-contraction relative to the totally relaxed state (absence of the contracting agents).
Isolated rat heart (Langendorff)
Male Sprague Dawley rats were used for these studies (Harlan Interfauna Ibérica S.A., Barcelona, Spain). All animal protocols conformed to the European Union Guidelines for the Care and the Use of Laboratory Animals (European Union Directive 2010/63/EU) and were approved by the Institute's Animal Care and Use Committee (Comité de Ética de la Investigación, Universidad Autónoma de Madrid). Hearts were perfused in a Langendorff apparatus as described previously [30] . Briefly, hearts were removed from Sprague Dawley rats (300-350 g) under anaesthesia with i.p. sodium pentobarbital (100 mg/kg) and after i.v. injection of heparin (1000 UI). Next, the ascending aorta was cannulated and the heart was subjected to retrograde perfusion with Krebs buffer at 37°C. Perfusion was kept at a constant flow rate of 11-15 ml/min. to provide a basal CPP of 60-70 mmHg. CPP was measured through a lateral connection in the perfusion system. Changes in CPP were recorded using a Mac Lab System/8e program (AD Instruments Inc, Milford, MA, USA) at a sample rate of 0.5 sec. After a 15-min. equilibration period with constant flow perfusion, U46619 (30-60 nM) was infused to achieve a sufficiently high CP. CPP increased from low basal levels (<70 mmHg) to 144 ± 3 mmHg (n = 10)., and when the CPP was stable, BK (0.01-1 nM) alone or in combination with SKA-111 (1 μM) was added to the perfusate and falls of CPP were recorded. In other series, SKA-111 was infused alone at a higher concentration of 10 μM.
Compounds and chemicals
Compounds were purchased from Sigma/Aldrich, Tocris, Fluorochem, Alfa Aesar, or synthesized in house (HW's laboratory: TRAM-34 [31] , SKA-111, SKA-121 [25] ; RB's laboratory: RA-2 [32] ). Stock solutions (at 1 or 10 mM) were prepared with DMSO, and the final DMSO concentration was always <0.5%, if not stated otherwise.
Statistics
Data are given as mean ± S.E.M. For comparison of data sets, we used unpaired or paired two-tailed Student's t-test or, in case of multiple comparisons, we used one-way ANOVA followed by the Tukey post hoc test. Statistical significance was considered for p-values of <0.05.
Results

Gene expression of K Ca 3.1 and K Ca 2 channels in PCAEC
RT-PCR analysis showed that freshly isolated PCAEC express the K Ca 3.1 and K Ca 2.3 subtypes as well as K Ca 2.2 ( fig. 1 ), providing additional evidence for mRNA expression of these channels in PCA endothelial cells [33, 34] .
Patch-clamp electrophysiology on primary PCAEC
We performed 'whole-cell' patch-clamp experiments on primary PCA endothelial cells (PCAEC). In single cells, infusion of calcium into the cells via the patch-pipette activated K + -outward currents that were voltage independent and showed inward rectification at positive membrane potentials ( fig. 2A) , thus resembling key electrophysiological properties of K Ca 3.1 channels [1, 2, 35] . Such current activation was not seen ( fig. 2A ) when we used a pipette solution with a free calcium concentration of 100 nM, which is below the threshold for K Ca 3.1 channel activation ( fig. 2A ).
The novel positive-gating modulator, SKA-111, with 120 times higher selectivity for K Ca 3.1 over K Ca 2 channels [25] Potentiated currents were sensitive to the classical K Ca 3.1 blocker, TRAM-34 [31] (1 μM, 52 ± 5% blockage of SKA-111-activated currents, fig. 2B , and 78 ± 7% blockage of SKA-121-activated currents, summary data in fig. 2C ). The K Ca 2 blocker UCL-1684 [36] (1 μM) had small additional blocking effects ( fig. 2B,C) . The negative-gating modulator, RA-2 (1 μM), that directly suppresses positive-gating modulation [32] potently blocked all K Ca current (not shown) and a small TRAM-34/UCL-1684-resistant K Ca current ( fig. 2B,C) , which may suggest incomplete block of porcine K Ca 3.1 by the pore blocker, TRAM-34 [37] .
We conducted a series of whole-cell patch-clamp experiments to show that calcium mobilizations to BK or 5-HT were also able to activate K Ca 3.1 ( fig. 3A) and that positivegating modulation of K Ca 3.1 further potentiated these currents. We found that BK ( fig. 3A , left) caused transient activation of outward currents that were long-lastingly augmented by SKA-121. In contrast, 5-HT produced only small outward currents under these conditions. Interestingly, SKA-121 produced large K Ca 3.1 currents also independently of BK and 5-HT ( fig. 3A, right) that suggested some minor basal K Ca 3.1 activity in these isolated cells, which could be potentiated by SKA-121.
Next, we conducted a series of current-clamp experiments on primary PCAEC clusters to investigate whether K Ca 3.1 positive-gating modulators augment membrane potential changes in response to BK and 5-HT. As shown in fig. 3B , we first tested the effects of 5-HT and BK alone and found that 5-HT (1 μM) or BK (1 μM) shifted membrane potentials from depolarized values (≈1 mV) to negative values, with 5-HT producing small responses (≈Δ −10 mV) and BK producing stronger responses (≈Δ−27 mV). The negative-gating modulator, RA-2, reversed the responses. In contrast, the positive-gating modulator, SKA-121, augmented the agonist-induced response (≈Δ−65 mV, p < 0.05; for trace, see fig.   3B ). This augmented response was likewise sensitive to RA-2. Importantly, SKA-121 was capable of producing hyperpolarization by itself. However, the amplitude of this hyperpolarization was smaller (≈Δ−42 mV) than the amplitudes seen after stimulation of BK in combination with SKA-121 (see traces in fig. 3B ). Moreover, the time course of hyperpolarization was different: BK elicited maximal responses within a few seconds ('timeto-peak', fig. S1 ), which can be expected for an agonist that binds to its GPCR and causes rapid IP 3 -mediated calcium release from the endoplasmic reticulum. In contrast, maximal responses to SKA-121 were achieved after approximately half a minute. The ability of SKA-121 to produce hyperpolarization in its own right can be explained by the activation of a few K Ca 3.1 channels exhibiting basal activity and normally only causing insignificant membrane potential changes but giving rise to a slow hyperpolarization response when potentiated by SKA-121.
EDH-type relaxation
Isometric tension measurements on large PCA in the presence of L-NNA and INDO to block NO and prostacyclin syntheses showed that contractions of PCA in response to 5-HT (1 μM) were of similar amplitude in the presence of SKA-111 (1 μM) or SKA-121 (1 μM) as those in the presence of the vehicle, DMSO (fig. S2A) . Thus, SKA-111 and SKA-121 at concentrations ≤1 μM at which the compounds selectively activate K Ca 3.1 did not influence contraction or produce vasorelaxation on their own.
With respect to endothelium-dependent EDH-type relaxation, SKA-111 and SKA-121 significantly augmented the BK-induced EDH-type relaxation in large PCA ( fig. 4A , for summary data; fig. S3 for original traces) . Fitting of the data revealed a left shift of the concentration-response curve (see table S1 for EC 50 values). TRAM-34 (1 μM) reduced the SKA-111-potentiated response ( fig. 4B ) and the combination of TRAM-34 and UCL-1684 (1 μM) had no additional effect. Data for SKA-121 are shown in fig. S4A . RA-2, a pannegative-gating modulator of both KCa3.1 and KCa2 channels, was equally effective in inhibiting the SKA-111-potentiated BK response (fig. S4B) . BK-induced relaxation in the absence of SKA-111 and SKA-121 ( fig. S4C,D) was inhibited by the combination of TRAM-34 and UCL-1684 as well as by RA-2.
None of the compounds significantly altered KCl-induced contractions and sodium nitroprusside-induced relaxations in large PCA ( fig. S2B,C) .
In small porcine coronary arteries, we found essentially the same: 1 μM SKA-111 by itself did not change U46619-induced contractions (n = 6) ( fig. S5 ), but SKA-111 markedly leftward-shifted concentration-response curves for BK-induced EDH responses ( fig. 4C ; for EC 50 values, see table S1). In the presence of TRAM-34 or the combination of TRAM-34 and UCL1684, SKA-111 did not change the concentration responses for BK ( fig. 4C ).
Together, these data demonstrate that BK selectively activates K Ca 3.1 to produce EDH-type relaxation and that positive-gating modulation of K Ca 3.1 is capable of potentiating this response in large-and small-calibre PCA.
Endothelium-dependent relaxation with NO and prostaglandin syntheses intact
In another series of experiments, we omitted blockers of NO and prostaglandin syntheses from the bath solution in order to evaluate the effects of the channel modulators with uncompromised synthesis of NO and the vasorelaxant prostacyclin. Positive-gating modulation of K Ca 3.1 showed a trend to potentiate BK-induced relaxations in the large PCA, although the difference did not reach a statistical significance ( fig. S6A ). Yet, such a trend was not seen when testing a positive-gating modulator of K Ca 3.1 in combination with the negative-gating modulator of K Ca 3.1, RA-2 ( fig. S6B ; for calculated EC 50 values, see table S1). In contrast, in the small PCA, SKA-111 effectively leftward-shifted concentration-response curves for BK under these conditions ( fig. 4D ) as it did in the presence of L-NAME and INDO. TRAM-34 alone or the blocker combination, TRAM-34 and UCL1684, suppressed this potentiation ( fig. 4D ).
Together, these data suggested that K Ca 3.1-selective positive-gating modulation also caused a significant potentiation of endothelium-dependent relaxations in small-calibre PCA when NO/prostaglandin synthesis was intact.
Experiments in isolated rat hearts
We next performed Langendorff experiments on rat hearts and tested whether positive-gating modulation of K Ca 3.1 potentiates BK-induced vasodilation in the coronary vascular bed (measured as a decrease in coronary perfusion pressure (CPP)). BK evoked reduction in CPP in a concentration-dependent fashion ( fig. 5 ). Co-infusion of SKA-111 at 1 μM significantly potentiated this response at 1 nM BK by 14% (≈10 mmHg), but not at lower BK concentrations ( fig. 5 ). Like in myography experiments, infusion of 1 μM SKA-111 alone did not change perfusion pressure (not shown). However, at a higher concentration of 10 μM, at which SKA-111 becomes less selective and can activate K Ca 2 channels, SKA-111 caused a substantial fall in CPP (−61 ± 2 mmHg, n = 4) that was clearly different from vehicle control (0.1% DMSO, −12 ± 2 mmHg, n = 2). This fall in CPP was as pronounced as the fall caused by a high BK concentration of 100 nM ( fig. S7 ).
In sum, these data suggest that selective positive-gating modulation of K Ca 3.1 by SKA-111 is capable of improving BK-induced coronary dilations in the isolated rat heart.
Discussion
The goal of the present study was to test whether two new positive-gating modulators, SKA-111 and SKA-121, with an improved selectivity profile for K Ca 3.1 over K Ca 2 channels could improve endothelial hyperpolarization and endothelium-dependent vasorelaxation in coronary arteries. We found that (1) PCAEC exhibited calcium-dependent activity of K Ca 3. Together, the present data suggest that K Ca 3.1-selective positive-gating modulators have potential utility for pharmacological manipulation of blood flow in the coronary circulation.
Endothelial K Ca 3.1 and K Ca 2.3 channels have been reported to mediate a significant part of EDH-type relaxations in response to receptor stimulation in rodents, pigs and human beings (for in-depth review, see [12, 38] ). However, subtype-specific roles of K Ca 3.1 in endothelium-dependent relaxations in the coronary circulation have not been established so far, and it remains unclear whether selective positive-gating modulation of K Ca 3.1 elicits vasorelaxation in the coronary arteries and/or potentiates agonist-induced vasorelaxation. The main outcome of the present in vitro study on PCA was that we could demonstrate that K Ca 3.1 channels contribute to BK-induced EDH-type relaxation in small-calibre PCA in a substantial fashion and that this contribution could be further potentiated by SKA-111 and SKA-121. A major role of K Ca 2.3 was not evident for these EDH-type responses in PCA because the K Ca 3.1 blocker TRAM-34 inhibited the response, while the K Ca 2 blocker, UCL-1684, in combination with TRAM-34 had no additional effects on either the potentiated response or the non-potentiated response. Yet, it is worth to mention that inhibition of K Ca 3.1 did not completely suppress EDH-type relaxation, suggesting that other endothelium-derived relaxation factors such as prostacyclin or diffusible EDHF(s) [4, 39, 40] may play additional roles here. We further found that positive-gating modulation of K Ca 3.1 was still able to augment BK-induced relaxation when nitric oxide and prostaglandin syntheses were intact. This was particularly evident in small-calibre PCA while potentiation was only seen by trend in the large-calibre PCA. This suggests that positive-gating modulation of K Ca 3.1 in the porcine heart is an effective way to improve endotheliumdependent relaxation in a physiological setting as well as under conditions of compromised NO or prostacyclin synthesis or action.
It is worth mentioning that SKA-111 and SKA-121 were unable to produce relaxation by themselves in PCA. This was unexpected because positive-gating modulation by SKAs was capable of producing significant hyperpolarization of PCAEC in vitro. However, it needs to be considered that freshly isolated endothelial cells are in an altered state (as indicated by their depolarized membrane potential) and slow hyperpolarization to SKAs may result from potentiating background K Ca 3.1 activity due to elevated basal [Ca 2+ ] i . Alternatively, positive-gating modulation of K Ca 3.1 may have a stronger vasorelaxant impact in a situation of endothelial depolarization in order to restore the endothelial resting membrane potential and to provide a negative feedback (repolarization) on agonist-induced depolarization and tone as suggested previously [41] . The Langendorff experiments on isolated rat heart largely agree with our findings from vessel myography by showing that K Ca 3.1-selective positivegating modulation was capable of potentiating BK-induced reduction in coronary resistance.
Conclusions
Coronary artery disease is associated with compromised coronary blood flow and myocardial ischaemia. Therefore, from the translational clinical perspective, selective positive-gating modulators of K Ca 3.1 could be of therapeutic value to reverse ischaemia and improve selectively endothelium-dependent and/or agonist-induced vasodilation in the coronary circulation.
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